circSCAP-encoded SCAP-129aa mediates platinum resistance in triple-negative breast cancer via the PI3K/AKT pathway
Science China Life Sciences · 2026-03 · 69 (3) · 921-936
DOI: 10.1007/s11427-024-2946-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science China Life Sciences, online erschienen am 28.08.2025. Verfasst von Qi Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Ya…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) often acquires resistance to platinum-based chemotherapy, presenting significant challenges to therapeutic management and adversely affecting patient survival. In such refractory cases, even advanced treatment modalities often exhibit diminished efficacy. This study aims to elucidate the molecular mechanisms underlying platinum resistance. Circular RNA circSCAP was found to be markedly upregulated in platinum-resistant TNBC and shown to encode a peptide, SCAP-129aa, which is likewise elevated in resistant tumors. Functional analyses revealed that silencing circSCAP in resistant tumors restores sensitivity to platinum-based chemotherapy, whereas its overexpression in sensitive tumors induces resistance. Mechanistically, SCAP-129aa directly interacts with the SH2C domain of PIK3R2, inhibiting its ubiquitination and subsequent degradation. This interaction stabilizes PIK3R2 protein and activates the PI3K/AKT signaling pathway, a key mediator of chemoresistance. Notably, in vivo studies further indicated that either silencing circSCAP or co-administering the PIK3R2 inhibitor SAR-260301 with platinum significantly improves treatment efficacy in resistant TNBC models. These findings establish circSCAP and SCAP-129aa as promising biomarkers and potential therapeutic targets for overcoming platinum resistance in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Ch…
- Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
- Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China. liuq77@mail.sysu.edu.cn.
Zitieren
APA
Wang, Q., Li, Y., Yang, Z., Yang, W., Liu, Y., Jin, L., Li, S., Shi, Q., Cai, Z., Ouyang, Y., Wu, M., Liu, R., Zhu, M., Lin, J., Wong, L. L., Wang, L., Gan, H., & Liu, Q. (2026). circSCAP-encoded SCAP-129aa mediates platinum resistance in triple-negative breast cancer via the PI3K/AKT pathway. Science China Life Sciences, 69(3), 921-936. https://doi.org/10.1007/s11427-024-2946-1
Vancouver
Wang Q, Li Y, Yang Z, Yang W, Liu Y, Jin L, et al. circSCAP-encoded SCAP-129aa mediates platinum resistance in triple-negative breast cancer via the PI3K/AKT pathway. Science China Life Sciences. 2026;69(3):921-936. doi:10.1007/s11427-024-2946-1
BibTeX
@article{Wang2026,
author = {Wang, Qi and Li, Yudong and Yang, Zhuangqiu and Yang, Wang and Liu, Yujie and Jin, Liang and Li, Shunying and Shi, Qianfeng and Cai, Zijie and Ouyang, Yiye and Wu, Mengzi and Liu, Ruiquan and Zhu, Mengdi and Lin, Jinna and Wong, Lok Lam and Wang, Linghan and Gan, Huipei and Liu, Qiang},
title = {circSCAP-encoded SCAP-129aa mediates platinum resistance in triple-negative breast cancer via the PI3K/AKT pathway},
journal = {Science China Life Sciences},
year = {2026},
volume = {69},
number = {3},
pages = {921--936},
doi = {10.1007/s11427-024-2946-1}
}
EUVIMED